THU0577 Tocilizumab monotherapy for adult onset still's disease – results of 52-week treatment of a prospective, single-center, single-arm, open trial

Abstract

BackgroundAdult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. Corticosteroids still provide mainstay AOSD therapy despite various adverse effects. Recently, AOSD patients have been successfully treated with...